semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 0.0-75.0,  Breast Cancer Stage III Ability to understand the study procedures and contents, and willingness to voluntarily sign the written informed consent form; 2. Age≤75 years old, female; 3. Histologically confirmed breast cancer; 4. Histologically or cytologically confirmed ipsilateral supraclavicular lymph node metastasis； 5. cT0-T3； 6. low and moderate risk for anesthesia  Absolute and relative contraindication for surgery or radiation； 2. existing distant metastasis before surgery； 3. non-invasive breast cancer； 4. with contralateral breast cancer； 5. Previous history of breast cancer or other malignancies； 6. ECOG≥2； 7. inflammatory breast cancer； 8. pregnancy； 9. any serious complications which caused patients not suitable to participate this study
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Female have aged 18 years old or older have DCIS or Invasive breast cancer that is eligible for breast-conserving surgery have not had previous chest radiotherapy understand the study purpose, requirements, and risks able and willing to give informed consent  None
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Confirmed diagnosis of HER2-positive breast cancer, and hormonal and PD-L1 status, as documented through central testing of a representative tumor tissue specimen Primary breast tumor size of > 2 cm by any radiographic measurement Stage at presentation: T2-T4, N1-N3, M0 as determined by AJCC staging system, 8th edition Pathologic confirmation of nodal involvement with malignancy must be determined by fine needle aspiration or core-needle biopsy. Surgical excision of lymph nodes is not permitted Patients with multifocal tumors are eligible provided at least one focus is sampled and centrally confirmed as HER2-positive Patients with multicentric tumors are eligible provided all discrete lesions are sampled and centrally confirmed as HER2-positive Eastern Cooperative Oncology Group Performance Status of 0 or 1 Baseline LVEF >= 55% measured by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scans Adequate hematologic and end-organ function obtained within 14 days prior to initiation of study treatment For women of childbearing potential: agreement to remain abstinent or use contraceptive methods, and agreement to refrain from donating eggs  Prior history of invasive breast cancer Stage IV (metastatic) breast cancer Patients with synchronous bilateral invasive breast cancer Prior systemic therapy for treatment of breast cancer Previous therapy with anthracyclines or taxanes for any malignancy Ulcerating or inflammatory breast cancer Undergone incisional and/or excisional biopsy of primary tumor and/or axillary lymph nodes Sentinel lymph node procedure or axillary lymph node dissection prior to initiation of neoadjuvant therapy History of other malignancy within 5 years prior to screening, with the exception of those patients who have a negligible risk of metastasis or death Cardiopulmonary dysfunction
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Gastric Carcinoma Pathologically or cytologically confirmed gastric or residual gastric or gastroesophageal junction carcinoma; 2. Patients received apatinib treatment at least once  No specific in this real world study
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Colorectal Medullary Carcinoma colorectal cancer diagnosis, medullary carcinoma  none
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 60.0-80.0,  Vitamin D Deficiency Postmenopausal Caucasian Total plasma 25-hydroxy vitamin D < 50 nmol/L Understand oral and written Danish Able to consent  Known allergic reaction/intolerance to Vitamin D supplementation / milk products / juice Known chronic kidney disease (creatinine > 90 µmol/L), previous kidney transplantation or known kidney artery stenosis Known liver disease Known gastrointestinal malabsorption Current malignant disease Hypercalcemia (ionised calcium ≥ 1.33 mmol/L) Treatment with diuretics, lithium or current use of steroids Current use of calcium and/or vitamin D supplementation Planned travel during the intervention period to areas where sun exposure is expected Use of solarium
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer ER-positive and/or PR-positive breast cancer HER2-negative breast cancer Unresectable locally advanced or metastatic breast cancer Confirmed disease progression while in the last aromatase inhibition-containing regimen in the metastatic setting At least one taxane or anthracycline regimen in either the adjuvant or the neoadjuvant setting Patients with no prior line of chemotherapy in the metastatic setting At least 1 and up to 3 prior lines of endocrine therapy in the metastatic setting ECOG score 0 or 1 Patients have adequate bone marrow and organ function Patients must have measurable disease (RECIST v.1.1)  Have received radiation therapy or limited-field palliative radiotherapy within two weeks prior to Cycle 1, Day 1, or patients who have not recovered from radiotherapy-related toxicities Have received prior chemotherapy for locally advanced or metastatic disease Have peripheral neuropathy grade 2 or greater QTc > 480 msec on basal assessments, history of congenital or personal history of long QT syndrome, Brugada syndrome, or Torsade de Pointes (TdP), or uncontrolled electrolyte disorders Child-bearing potential women not using highly effective methods of contraception Known hypersensitivity to eribulin, endocrine therapy or its excipients Other malignancies within the previous two years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of cervix or breast Known uncontrolled metastases to the central nervous system (CNS) or any progressing CNS disease Have a serious concomitant systemic disorder incompatible with the study Major surgical procedure or significant traumatic injury within 28 days prior to randomization
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Triple Negative Breast Cancer Early-stage Breast Cancer HER2-positive Breast Cancer The patient must have consented to participate and must have signed and dated an appropriate IRB-approved consent form that conforms to federal and i institutional guidelines for the pre-entry research core biopsy for CELx HSF testing and for initiating chemotherapy Patients must be female Patients must be ≥ 18 years old Patient must have an ECOG performance status of 0 or 1 The diagnosis of invasive adenocarcinoma of the breast must have been made by core needle biopsy The primary breast tumor must be palpable and measure ≥ 1.0 cm on physical exam The regional lymph nodes can be cN0 or cN1 The tumor size can be T1c or T2 Ipsilateral axillary lymph nodes must be evaluated by imaging (mammogram, ultrasound, and/or MRI) within 6 weeks prior to initiating chemotherapy. If suspicious or abnormal, FNA or core biopsy is recommended, also within 6 weeks prior to initiating chemotherapy. Findings of these evaluations will be used to determine the nodal status prior to initiating chemotherapy Nodal status  T3 or T4 tumors including inflammatory breast cancer FNA alone to diagnose the breast cancer Excisional biopsy or lumpectomy performed prior to initiating chemotherapy Surgical axillary staging procedure prior to initiating chemotherapy. Pre neoadjuvant therapy sentinel node biopsy is not permitted. (FNA or core biopsy is acceptable.) Definitive clinical or radiologic evidence of metastatic disease. Required imaging studies must have been performed within 6 weeks prior to initiating chemotherapy Synchronous bilateral invasive breast cancer. (Patients with synchronous and/or previous contralateral DCIS or LCIS are eligible.) Any previous history of ipsilateral invasive breast cancer or ipsilateral DCIS. (Patients with synchronous or previous ipsilateral LCIS are eligible.) Previous therapy with anthracycline, taxanes, trastuzumab, or other HER2 targeted therapies for any malignancy Any sex hormonal therapy, e.g., birth control pills, ovarian hormone replacement therapy, etc. (These patients are eligible if this therapy is discontinued prior to initiating chemotherapy.)
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Lymph Node Metastases Phase I: 1. aged from 18 years old to 80 years old; 2. the primary treatment of patients with right or bilateral PTC; 3. patients will voluntarily enter the study after informed consent. Phase II: 1. aged from 18 years old to 80 years old; 2. the primary treatment of patients with right or bilateral PTC predicted to have no LN-prRLN metastasis by the "prediction model of LN-prRLN"; 3. patients will voluntarily enter the study after informed consent  patients refused to participate in the study; 2. non first operation patients; 3. other malignant tumor history; 4. distant metastasis; 5. history of neck trauma
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Female patients with a histological diagnosis of breast cancer with known HER2 status ((8 positive and 8 negative). 2. Written informed consent prior to admission in the study. 3. Target lesion diameter of ≥15mm that has not been previously irradiated. 4. Female patients aged ≥ 18 years of age. 5. For all patients: histologically confirmed locally advanced/metastatic breast cancer with a biopsy within the last 12 months confirming HER2 status by either immunohistochemistry (IHC), Silver In Situ Hybridization (SISH) or Fluorescent In Situ Hybridization (FISH). 6. ECOG performance status 0-2 7. Negative urine pregnancy test (within 2 hours prior to injection of imaging agent) in women of child bearing age and willingness to use contraception (barrier, abstinence, non-hormonal) for 3 weeks after injection of [18F]GE-226 8. Life expectancy > 3 months 9. Adequate organ function as defined by Hb≥10g/L WBC≥3.0 x 109/L PLT≥80 x 109/L Serum creatinine ≤1.4mg/dl SGOT and SGPT ≤2 x ULN Total bilirubin ≤ 2 x ULN or 3.0 mg/dl in patients with Gilbert's syndrome 10. Patients must have been appropriately staged using FDG-PET within 42 days of study entry and additional imaging according to local standard of care  Pregnant or lactating women. 2. History of cardiac disease (myocardial infarction, arrhythmias requiring therapy, symptomatic valvular disease, cardiomyopathy, or pericarditis). 3. Evidence of significant medical condition or laboratory finding which, in the opinion of the Investigator, makes it undesirable for the patient to participate in the trial. 4. Participants with severe claustrophobia or who are unable to lie flat or fit into the scanner (≥350 lbs (160 Kg)). 5. Prior use within 14 days of enrolment or concurrent therapy with any other investigational agent. 6. Patients classified as radiation workers 7. Patients on therapeutic doses of anticoagulants, or with a raised prothrombin time
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Bile Duct Neoplasms Intraductal Papillary Mucinous Neoplasm Clinical diagnosis of IPNBs ECOG Performance status of 0, 1, or 2 Adequate liver function, bilirubin < 1.5 times ULN, ALT or AST < 2.5 times ULN Adequate renal function: creatinine < 1.8 Must be at least 18  Diagnosis of hepatic mucinous cystadenoma (MCN) Complicated with other Malignancy Pregnancy
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Relationship and Consistency Analysis breast cancer in stage I-III, tumor size>0.5cm 2. lymph nodes negative 3. hormone receptor positive （ER+/PR+,ER+/PR-,ER-/PR+） 4. HER2 negative（IHC 0 or +， FISH negative） 5. receive endocrine therapy only 6. enough FFPE samples within 10 years（3~6 10μm ） 7. patients with integrated medical records  Tumor cells <5% 2. Isolated RNA<500ng
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Biopsy Female subjects ≥ 18 years old with ultrasound visible breast abnormalities (BI-RADS 3*, 4A, 4B, 4C, and 5) referred for ultrasound-guided core needle biopsy or fine needle aspiration *note that while a BI-RADS 3 assessment is probably benign, a subset of patients with this assessment choose to undergo biopsy rather than follow up imaging) Willing and able to provide informed consent  Lesions located in the darkly pigmented nipple-areolar complex area Subjects with breast implants Abnormality in the mirror image location of the contralateral breast Additional abnormalities in the same region of the breast that would be included in US-guided DOT imaging of the abnormality undergoing biopsy Previous breast irradiation of the mirror image location of the contralateral breast Lesions located at previous biopsy sites when biopsy occurred within the last six months Small lesions of less than 1 cm located at skin or close to the skin Pregnancy Superficial abnormalities located entirely within (i.e. less than) 5mm of the overlying skin